Published in BJU Int on July 01, 2013
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol (2010) 13.03
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res (2006) 4.71
Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 2.88
Achieving equal standards in medical student education: is a national exit examination the answer? Med J Aust (2005) 2.78
Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol (2009) 2.77
Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol (2006) 2.59
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer (2013) 2.51
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol (2010) 2.23
Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial. J Natl Cancer Inst (2010) 2.12
18F-fluorodeoxyglucose--positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer. Urology (2014) 2.09
Markers of cardiovascular risk are not changed by increased whole-grain intake: the WHOLEheart study, a randomised, controlled dietary intervention. Br J Nutr (2010) 1.99
Attrition and bias in the MRC cognitive function and ageing study: an epidemiological investigation. BMC Public Health (2004) 1.97
Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf) (2008) 1.78
What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile? Lancet Oncol (2005) 1.77
How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. J Clin Oncol (2010) 1.76
Oncology health information quality on the Internet: a multilingual evaluation. Ann Surg Oncol (2011) 1.73
Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells. Cancer Immunol Immunother (2009) 1.66
The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Res (2008) 1.64
Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood (2004) 1.54
Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res (2009) 1.52
Contemporary management of renal cell carcinoma (RCC) in Victoria: implications for longer term outcomes and costs. BJU Int (2013) 1.50
Uro-oncology multidisciplinary meetings at an Australian tertiary referral centre--impact on clinical decision-making and implications for patient inclusion. BJU Int (2014) 1.49
An investigation of whether factors associated with short-term attrition change or persist over ten years: data from the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). BMC Public Health (2006) 1.49
Breast and prostate cancer: more similar than different. Nat Rev Cancer (2010) 1.48
Patterns of care for men diagnosed with prostate cancer in Victoria from 2008 to 2011. Med J Aust (2013) 1.43
Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clin Cancer Res (2004) 1.41
Fulvestrant: spreading the word, but not too thinly. Lancet (2003) 1.37
Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. J Thorac Oncol (2011) 1.35
Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev (2012) 1.32
Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review. Support Care Cancer (2006) 1.31
Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol (2007) 1.29
Promising results with chemoradiation in patients with sinonasal undifferentiated carcinoma. Head Neck (2004) 1.26
Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. Blood (2003) 1.25
Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board. Clin Lung Cancer (2012) 1.22
IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother (2008) 1.22
Predicting clinical outcome through molecular profiling in stage III melanoma. Clin Cancer Res (2008) 1.17
Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Res (2009) 1.16
Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res (2009) 1.16
Screening for prostate cancer: explaining new trial results and their implications to patients. Med J Aust (2009) 1.16
The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun (2004) 1.15
Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans. J Pharmacol Exp Ther (2003) 1.13
Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancer. Psychooncology (2007) 1.13
Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc Natl Acad Sci U S A (2004) 1.11
The Ludwig institute for cancer research Melbourne melanoma cell line panel. Pigment Cell Melanoma Res (2013) 1.08
Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. Cancer Immun (2003) 1.08
Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate. Eur J Cancer (2010) 1.05
Clinical applications of molecular imaging in sarcoma evaluation. Cancer Imaging (2005) 1.05
Positron emission tomography and molecular imaging of the prostate: an update. BJU Int (2006) 1.03
Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1. Immunol Cell Biol (2006) 1.03
ATP gradients inhibit the migratory capacity of specific human dendritic cell types: implications for P2Y11 receptor signaling. Blood (2003) 1.03
A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen. Clin Cancer Res (2007) 1.01
An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer. Am J Clin Oncol (2009) 1.01
Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma. Clin Cancer Res (2005) 1.00
Longitudinal nasopharyngeal carriage and antibiotic resistance of respiratory bacteria in indigenous Australian and Alaska native children with bronchiectasis. PLoS One (2013) 0.99
Flt3 ligand expands CD4+ FoxP3+ regulatory T cells in human subjects. Eur J Immunol (2012) 0.99
Validity, responsiveness, and minimal important difference for the SF-6D health utility scale in a spinal cord injured population. Value Health (2008) 0.98
Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas. Clin Cancer Res (2013) 0.98
Are cancer drugs less likely to be recommended for listing by the Pharmaceutical Benefits Advisory Committee in Australia? Pharmacoeconomics (2010) 0.97
Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography. BJU Int (2005) 0.97
Need for global partnership in cancer care: perceptions of cancer care researchers attending the 2010 australia and Asia pacific clinical oncology research development workshop. J Oncol Pract (2011) 0.96
A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma. PLoS One (2012) 0.96
Health-related quality of life and inflammatory markers in malignant pleural mesothelioma. Support Care Cancer (2012) 0.95
Use of tamoxifen in advanced-stage hepatocellular carcinoma. A systematic review. Cancer (2005) 0.94
Gender-specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood. Int J Cancer (2009) 0.94
A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design. Cancer Res (2009) 0.94
Otitis media in children vaccinated during consecutive 7-valent or 10-valent pneumococcal conjugate vaccination schedules. BMC Pediatr (2014) 0.94
Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. Anticancer Drugs (2008) 0.93
Health status rated with the Medical Outcomes Study 36-Item Short-Form Health Survey after spinal cord injury. Arch Phys Med Rehabil (2005) 0.93
A robust human T-cell culture method suitable for monitoring CD8+ and CD4+ T-cell responses from cancer clinical trial samples. J Immunol Methods (2004) 0.93
Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis. BJU Int (2012) 0.93
Peripheral primitive neuroectodermal tumor arising from the seminal vesicle. Urol Int (2008) 0.92
Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor. Oncogene (2004) 0.92
Patients' preferences for chemotherapy in non-small-cell lung cancer: a systematic review. Lung Cancer (2010) 0.92
Implementing patient question-prompt lists into routine cancer care. Patient Educ Couns (2011) 0.92
Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors. BMC Med Genomics (2013) 0.91
Positron emission tomography (PET), immuno-PET and radioimmunotherapy in renal cell carcinoma: a developing diagnostic and therapeutic relationship. BJU Int (2006) 0.91
Paranasal sinus tumors: Peter MacCallum Cancer Institute experience. Head Neck (2004) 0.91
Perineural infiltration of cutaneous squamous cell carcinoma and basal cell carcinoma without clinical features. Int J Radiat Oncol Biol Phys (2010) 0.91
Human perforin mutations and susceptibility to multiple primary cancers. Oncoimmunology (2013) 0.90
Intensity modulated radiation therapy dose painting for localized prostate cancer using ¹¹C-choline positron emission tomography scans. Int J Radiat Oncol Biol Phys (2012) 0.90
Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT. Urol Oncol (2009) 0.90
Positive surgical margins: rate, contributing factors and impact on further treatment: findings from the Prostate Cancer Registry. BJU Int (2014) 0.89
A randomized controlled trial of a standardized educational intervention for patients with cancer pain. J Pain Symptom Manage (2010) 0.89
Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy. Prostate (2009) 0.89
The Prostate Cancer Registry: monitoring patterns and quality of care for men diagnosed with prostate cancer. BJU Int (2012) 0.89
Human papillomavirus, smoking status and outcomes in tonsillar squamous cell carcinoma. Int J Cancer (2012) 0.88
ECSA/DPPA2 is an embryo-cancer antigen that is coexpressed with cancer-testis antigens in non-small cell lung cancer. Clin Cancer Res (2008) 0.88
Lung cancer clinicians' preferences for adjuvant chemotherapy in non-small-cell lung cancer: what makes it worthwhile? Lung Cancer (2011) 0.87
Comparing patients' and their partners' preferences for adjuvant chemotherapy in early breast cancer. Patient Educ Couns (2008) 0.87
Cell mates: paracrine and stromal targets for prostate cancer therapy. Nat Rev Urol (2013) 0.87
Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™. Cancer Immunol Immunother (2011) 0.87
Histopathological correlation of (11)C-choline PET scans for target volume definition in radical prostate radiotherapy. Radiother Oncol (2011) 0.87